Feng Zhang quietly starting new CRISPR-based company: report

CRISPR Nanoparticle
The news follows last week’s unveiling of a new CRISPR company, Mammoth Biosciences, co-founded by Jennifer Doudna. (MIT News)

Beam Therapeutics, a new Cambridge, Massachusetts-based startup co-founded by gene editing innovator Feng Zhang, has raised nearly $100 million in series A funding and early commitments, according to reporting from the Boston Business Journal.

Citing Pitchbook, the journal reported that Beam raised an initial $13 million from Arch Venture Partners and F-Prime Capital Partners. About another $85 million has been committed before any formal announcements, the report said.

The news followed last week’s unveiling of a new CRISPR company, Mammoth Biosciences, which will utilize gene-editing technology from the lab of co-founder Jennifer Doudna, who will also serve as chair of Mammoth’s science advisory board.

Sponsored By Syneos Health

Blazing a Trail to Clinical Trial Diversity: Four-Part Webinar Series from Syneos Health, Featuring Pharma, Clinical Research and Community Health Leaders

This series will identify obstacles that stifle appropriate patient diversity in trials; unpack the organizational overhaul needed; share how sponsors, patients & investigators have come together to overcome hurdles; and explore how policy innovations can move the industry forward.

Zhang and Doudna have been embroiled in an international legal dispute over the patents on CRISPR/Cas9 gene editing technology. Last year, the U.S. Patent and Trademark Office sided with the Broad Institute, Zhang’s institution, saying the inventions claimed by Broad were distinct from those asserted by Doudna and UC Berkeley.

RELATED: Special Report—The 25 most influential people in biopharma in 2015Jennifer Doudna, Emmanuelle Charpentier – Caribou Biosciences, CRISPR Therapeutics 

According to the Boston Business Journal’s report, Beam is pursing methods to more precisely edit individual base pairs without snipping the molecule’s double-helix structure.

An additional Zhang effort, Arbor Biotechnologies, recently announced $15.6 million in series A funding and a new CRISPR-associated enzyme, Cas13d, that might allow easier delivery to cells.

Mammoth, meanwhile, hopes to develop a CRISPR-based platform to detect DNA- and RNA-based biomarkers across a wide variety of disease areas. The company currently lists several investors but has not disclosed the amount of capital it has raised.